Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 59%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is a clinical-stage biopharmaceutical company with a promising pipeline of small molecules targeting genetically validated kinase targets in cancer. With the recent acceptance of the NDA for neladalkib by the FDA for ALK+ NSCLC patients and the upcoming presentation of data at ASCO for NVL-520 and NVL-655, the company appears to be on track for commercial success. Additionally, with a strong balance sheet and continued pipeline development, the company's stock presents a compelling investment opportunity for potential growth.

Bears say

Nuvalent is a clinical-stage biopharmaceutical company that is developing small molecules for patients with cancer, with all of its operations in the US. While their preclinical data for their ROS1 inhibitor, zidesamtinib, shows potential, their ALK inhibitor, neladalkib, has only shown a modest response rate in heavily pre-treated patients and may not be able to compete with other ALK inhibitors. With a current revenue forecast of only $68MM for neladalkib's potential launch in 2027, and a risk-adjusted discount rate of 15-30%, the company's future outlook is not favorable.

Nuvalent (NUVL) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 59% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 17 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.